Schering Corporation

Merck Sharp + Dohme Corp.

Schering-plough Veterinary Corporation

Leonore Catherine Witchey-Lakshmanan

Peter M Ihnat

Sydney O Ugwu

Vinay Radhakrishnan

Zezhi Jesse Shao

Varda E Sandweiss

Allan Chor-Lun Fan

Rong Gao

Daniel Charles Stewart

Varda Sandweiss

Disclosed are aqueous and lyophilized formulations containing SYN3 and methods of their use for treating bladder cancer.

SYN3 compositions and methods

In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Pharmaceutical formulations of antineoplastic agents

Processes of making and using pharmaceutical formulations of antineoplastic agents

Pharmaceutical formulations of antineoplastic agents and processes of making and using the same

This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.

Taste masking of oral quinolone liquid preparations using ion exchange resins

Growing community of inventors

Piscataway, NJ, United States of America

Leonore Catherine Witchey-Lakshmanan